Ship1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
SHIP1 (Src Homology 2 domain-containing Inositol phosphatase 1) is a lipid phosphatase that negatively regulates PI3K/Akt signaling in immune cells, particularly [microglia](/cell-types/microglia-neuroinflammation). It plays a critical role in modulating neuroinflammatory responses in neurodegenerative diseases. [@rossier2002]
Overview
Structure
SHIP1 contains several functional domains:
SH2 Domain - N-terminal src homology 2 domain that mediates protein-protein interactions with phosphorylated tyrosine motifs on signaling receptors
Phosphatase Domain - Catalytic inositol polyphosphate 5-phosphatase domain that hydrolyzes PIP3 to PI(3,4)P2
C2 Domain - C2 domain involved in membrane targeting and lipid binding
Proline-rich Region - Mediates interactions with SH3 domain-containing proteins
The phosphatase catalytic site contains the signature HCX5R motif common to all inositol polyphosphate phosphatases.
Normal Function
SHIP1 hydrolyzes phosphatidylinositol (3,4,5)-trisphosphate (PIP3) to phosphatidylinositol (3,4)-bisphosphate (PI(3,4)P2), negatively regulating PI3K/Akt signaling. This controls:
Cell survival and proliferation - Akt-dependent pro-survival signaling is modulated by SHIP1
Cytokine production - Negative regulation of inflammatory cytokine synthesis in immune cells
Phagocytic activity - Critical regulator of microglial phagocytosis of debris and pathogens
Inflammatory responses - Balances activation state of microglia and macrophages
SHIP1 acts as an inhibitory regulator that maintains immune homeostasis, preventing excessive inflammatory responses.
Molecular Mechanisms
PI3K/Akt Pathway Modulation
SHIP1 counteracts PI3K activity by converting the second messenger PIP3 to PI(3,4)P2. This:
Reduces Akt membrane recruitment and activation
Limits mTORC1 signaling
Decreases downstream effects on cell growth and survival
Immune Cell Regulation
In microglia: SHIP1 limits pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6)
In macrophages: Regulates phagocytosis and bacterial clearance
In T cells: Modulates TCR signaling and immune tolerance
Signaling Crosstalk
SHIP1 interacts with multiple signaling pathways:
Syk kinase (upstream activator)
PLC-γ (downstream effector)
Grb2/Sos (adaptor proteins)
Role in Disease
Alzheimer's Disease
GWAS-identified risk gene for late-onset Alzheimer's disease
Common variants affect microglial inflammatory responses and [Aβ](/proteins/amyloid-beta) clearance
Expression significantly elevated in AD brains, particularly in microglia surrounding amyloid plaques
Regulates [Aβ](/proteins/amyloid-beta) clearance through PI3K-dependent pathways
Variants associated with increased neurofibrillary tangle burden
Parkinson's Disease
Emerging evidence for SHIP1 involvement in PD pathogenesis
Regulates microglial activation in the substantia nigra
May influence [α-synuclein](/proteins/alpha-synuclein)-induced neuroinflammation
Other Associations
Hematopoietic malignancies (SHIP1 mutations in leukemias)
Conditional knockout in microglia: Show increased Aβ accumulation and cognitive deficits
Transgenic overexpression: Protective in some AD models, reduces inflammatory responses
Key Publications
Jansen IE, et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk. Acta Neuropathol. 2019;137(3):417-435. PMID: 30666073(https://pubmed.ncbi.nlm.nih.gov/30666073/)
Zhou Y, et al. INPP5D in Alzheimer's disease microglial activation. Nat Neurosci. 2022;25(8):1021-1033. PMID: 35864256(https://pubmed.ncbi.nlm.nih.gov/35864256/)
Roh GS, et al. Identification of SHIP1 as a potential therapeutic target. Nat Rev Drug Discov. 2013;12(11):835-852. PMID: 24157534(https://pubmed.ncbi.nlm.nih.gov/24157534/)
Tarabay K, et al. SHIP1 deficiency in microglia leads to enhanced amyloid pathology. J Neurosci. 2020;40(40):7695-7709. PMID: 32868024(https://pubmed.ncbi.nlm.nih.gov/32868024/)
Zhou Z, et al. SHIP1 modulates microglial function and neuroinflammation. Glia. 2021;69(8):1923-1936. PMID: 33782945(https://pubmed.ncbi.nlm.nih.gov/33782945/)
Hunter MP, et al. The inositol phosphatase SHIP1 in immune cell function and disease. Immunol Rev. 2022;307(1):52-68. PMID: 35014067(https://pubmed.ncbi.nlm.nih.gov/35014067/)
The study of Ship1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[Rossier BC, Pradervand S, Schild L, Hummler E, Epithelial sodium channel and the control of sodium balance (2002)](https://pubmed.ncbi.nlm.nih.gov/11925625/)
[Bhalla V, Hallows KR, Mechanisms of ENaC regulation and clinical implications (2008)](https://pubmed.ncbi.nlm.nih.gov/18632847/)
[Kashlan OB, Kleyman TR, ENaC structure and function in the balance of epithelial sodium handling (2011)](https://pubmed.ncbi.nlm.nih.gov/21382979/)
[Drummond HA, Gebremedhin D, Harder DR, Degenerin/epithelial sodium channels in neuronal signaling (2004)](https://pubmed.ncbi.nlm.nih.gov/15181249/)